Fate Therapeutics Company Profile (NASDAQ:FATE)

About Fate Therapeutics

Fate Therapeutics logoFate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FATE
  • CUSIP:
Key Metrics:
  • Previous Close: $3.07
  • 50 Day Moving Average: $2.79
  • 200 Day Moving Average: $2.07
  • 52-Week Range: $1.46 - $6.71
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.82
  • P/E Growth: 0.00
  • Market Cap: $88.70M
  • Outstanding Shares: 28,894,000
  • Beta: 0.73
Profitability:
  • Net Margins: -699.10%
  • Return on Equity: -90.94%
  • Return on Assets: -49.35%
Debt:
  • Debt-to-Equity Ratio: 0.29%
  • Current Ratio: 3.29%
  • Quick Ratio: 3.29%
Additional Links:
Companies Related to Fate Therapeutics:

Analyst Ratings

Consensus Ratings for Fate Therapeutics (NASDAQ:FATE) (?)
Ratings Breakdown: 8 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.17 (133.44% upside)

Analysts' Ratings History for Fate Therapeutics (NASDAQ:FATE)
Show:
DateFirmActionRatingPrice TargetDetails
9/22/2016Roth CapitalInitiated CoverageBuy$8.00View Rating Details
8/9/2016HC WainwrightReiterated RatingBuyView Rating Details
8/8/2016BMO Capital MarketsSet Price TargetBuy$4.00View Rating Details
6/21/2016Leerink SwannReiterated RatingOutperform$4.00View Rating Details
5/10/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
12/7/2015WedbushReiterated RatingOutperform$10.00View Rating Details
11/5/2015Cowen and CompanyReiterated RatingOutperformView Rating Details
10/6/2015Raymond James Financial Inc.Initiated CoverageOutperform$8.00View Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Fate Therapeutics (NASDAQ:FATE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2016        
8/8/2016Q216($0.32)($0.29)$1.02 million$1.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.25)($0.29)ViewN/AView Earnings Details
3/3/2016Q415($0.27)($0.26)$1.10 millionViewN/AView Earnings Details
11/3/2015Q315($0.30)($0.24)$1.00 millionViewN/AView Earnings Details
8/5/2015Q215($0.39)($0.33)ViewN/AView Earnings Details
5/7/2015Q115($0.37)($0.38)ViewListenView Earnings Details
3/12/2015Q414($0.31)($0.30)ViewListenView Earnings Details
11/11/2014($0.29)($0.30)ViewN/AView Earnings Details
8/12/2014Q214($0.37)($0.30)ViewN/AView Earnings Details
5/13/2014Q114($0.33)($0.34)ViewN/AView Earnings Details
3/17/2014Q413($0.27)($0.29)ViewN/AView Earnings Details
11/13/2013Q3($0.32)($4.81)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Fate Therapeutics (NASDAQ:FATE)
Current Year EPS Consensus Estimate: $-1.13 EPS
Next Year EPS Consensus Estimate: $-1.09 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.31)($0.27)($0.29)
Q2 20162($0.35)($0.33)($0.34)
Q3 20164($0.35)($0.29)($0.32)
Q4 20164($0.36)($0.23)($0.31)
Q1 20172($0.36)($0.25)($0.31)
Q2 20172($0.38)($0.26)($0.32)
Q3 20172($0.40)($0.27)($0.34)
Q4 20172($0.30)($0.28)($0.29)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Fate Therapeutics (NASDAQ:FATE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Fate Therapeutics (NASDAQ:FATE)
Insider Ownership Percentage: 13.66%
Institutional Ownership Percentage: 41.22%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/12/2014Peter D FlynnInsiderSell6,488$7.00$45,416.00View SEC Filing  
6/10/2014Peter D FlynnInsiderSell3,305$7.00$23,135.00View SEC Filing  
5/1/2014Peter D FlynnInsiderSell9,793$7.07$69,236.51View SEC Filing  
4/4/2014Peter D FlynnInsiderSell5,889$8.00$47,112.00View SEC Filing  
4/2/2014Christian WeyerInsiderSell10,000$9.02$90,200.00View SEC Filing  
4/1/2014J Scott WolchkoInsiderSell20,000$9.64$192,800.00View SEC Filing  
3/31/2014Daniel D ShoemakerCTOSell8,653$9.86$85,318.58View SEC Filing  
10/4/2013John MendleinDirectorBuy16,667$6.00$100,002.00View SEC Filing  
10/4/2013Venture Fund Vi Lp ArchMajor ShareholderBuy833,333$6.00$4,999,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Fate Therapeutics (NASDAQ:FATE)
DateHeadline
News IconUS FDA grants orphan drug status to Fate Therapeutics' ProTmune in allogeneic hematopoietic cell transplantation (NASDAQ:FATE)
www.pharmabiz.com - September 28 at 9:52 AM
News IconFDA Grants Orphan Drug Designation to Fate Therapeutics Product (NASDAQ:FATE)
sdbj.com - September 27 at 9:35 AM
streetinsider.com logoPre-Open Stock Movers 09/26: (ARRY) (CHMT) (GWPH) Higher; (PTIE) (DRRX) (SALE) Lower (more...) (NASDAQ:FATE)
www.streetinsider.com - September 26 at 5:08 PM
reuters.com logoBRIEF-Air Canada announces pricing of C$1.25 bln refinancing (NASDAQ:FATE)
uk.reuters.com - September 26 at 9:41 AM
publicnow.com logoFate Therapeutics Receives FDA Orphan Drug Designation for ProTmune™ in Allogeneic Hematopoietic Cell Transplantation (NASDAQ:FATE)
www.publicnow.com - September 26 at 9:41 AM
4-traders.com logoFate Therapeutics : and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T-Cell Immunotherapies (NASDAQ:FATE)
www.4-traders.com - September 25 at 4:30 PM
News IconExpert Analysts Position For: BioTime, Inc. (NYSEMKT:BTX) , Fate ... - Wall Street Times (press release) (NASDAQ:FATE)
www.wallstreetnews24.com - September 23 at 4:45 PM
nasdaq.com logoCan The Uptrend Continue for Fate Therapeutics (FATE)? - Nasdaq (NASDAQ:FATE)
www.nasdaq.com - September 23 at 4:45 PM
finance.yahoo.com logoCan The Uptrend Continue for Fate Therapeutics (FATE)? (NASDAQ:FATE)
finance.yahoo.com - September 23 at 4:44 PM
finance.yahoo.com logoCoverage initiated on Fate Therapeutics by ROTH Capital (NASDAQ:FATE)
finance.yahoo.com - September 22 at 5:01 PM
News IconFate Therapeutics Gains on Orphan Drug Designation Status For ProTmune (NASDAQ:FATE) - Post News (NASDAQ:FATE)
www.kentuckypostnews.com - September 22 at 10:31 AM
News IconShares in Focus: Fate Therapeutics, Inc. (NASDAQ:FATE) Earnings & Targets Update - Frisco Fastball (NASDAQ:FATE)
friscofastball.com - September 21 at 5:27 PM
fxpips.com logoNASDAQ Pre-Market Top Gainers and Losers Summary (NASDAQ:FATE)
www.fxpips.com - September 21 at 9:11 AM
kcregister.com logoHot Alert: Fate Therapeutics, Inc. (NASDAQ:FATE), Range Resources Corporation (NYSE:RRC), Haemonetics ... - KC Register (NASDAQ:FATE)
www.kcregister.com - September 19 at 3:53 PM
News IconLooking Ahead for Fate Therapeutics, Inc. (NASDAQ:FATE); Are These Shares Ready to Go Higher? - Frisco Fastball (NASDAQ:FATE)
friscofastball.com - September 19 at 9:38 AM
News IconWhat is the Street Saying About Fate Therapeutics, Inc. (NASDAQ:FATE)? - Frisco Fastball (NASDAQ:FATE)
friscofastball.com - September 19 at 9:38 AM
News IconKeen Investors Seek Information on Fate Therapeutics, Inc. (NASDAQ:FATE) - Duncan Research (NASDAQ:FATE)
www.duncanindependent.com - September 17 at 4:48 PM
News IconWhat are Brokerage Firms Saying About Fate Therapeutics, Inc. (NASDAQ:FATE)? - Frisco Fastball (NASDAQ:FATE)
friscofastball.com - September 17 at 4:48 PM
News IconStock Update, a Closer Look at Fate Therapeutics, Inc. (NASDAQ:FATE) - Duncan Research (NASDAQ:FATE)
www.duncanindependent.com - September 16 at 8:44 AM
News IconConsensus Take: Fate Therapeutics, Inc. (NASDAQ:FATE) Earnings & Ratings Watch - Frisco Fastball (NASDAQ:FATE)
friscofastball.com - September 16 at 8:44 AM
News IconSell-side is Weighing in on Fate Therapeutics, Inc. (NASDAQ:FATE) Earnings & Targets - Frisco Fastball (NASDAQ:FATE)
friscofastball.com - September 14 at 10:10 PM
News IconKeen Investors Narrowing Their Focus on Fate Therapeutics, Inc. (NASDAQ:FATE) - Duncan Research (NASDAQ:FATE)
www.duncanindependent.com - September 14 at 10:10 PM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: Fate Therapeutics, Inc. (NASDAQ:FATE) - Frisco Fastball (NASDAQ:FATE)
friscofastball.com - September 14 at 10:10 PM
News IconFate Therapeutics, Inc Pipeline Review, Industry Analysis, Size and Clinical trial 2016 - 2020 - Medgadget (blog) (NASDAQ:FATE)
www.medgadget.com - September 14 at 10:09 PM
reuters.com logoBRIEF-Aisling Capital IV Lp reports 5.1 pct passive stake in Protagonist Therapeutics as of Aug 16 (NASDAQ:FATE)
in.reuters.com - September 14 at 9:08 AM
News IconNew Broker Views On Fate Therapeutics, Inc. (FATE) - National Daily Press (NASDAQ:FATE)
www.nationaldailypress.com - September 13 at 9:50 AM
kcregister.com logoStock Runners: Cowen Group (NASDAQ:COWN), Fate Therapeutics (NASDAQ:FATE), NovaGold Resources Inc ... - KC Register (NASDAQ:FATE)
www.kcregister.com - September 12 at 9:49 AM
News IconAnalysts Place Fate Therapeutics, Inc. (NASDAQ:FATE) Under the Lens of the Microscope - Post News (NASDAQ:FATE)
www.kentuckypostnews.com - September 12 at 9:49 AM
News IconTrader's Round Up – Fate Therapeutics, Inc. (NASDAQ:FATE) , Caesars Acquisition Company (NASDAQ:CACQ) - Wall Street Times (press release) (NASDAQ:FATE)
www.wallstreetnews24.com - September 12 at 9:49 AM
capitalcube.com logoETF’s with exposure to Fate Therapeutics, Inc. : September 9, 2016 (NASDAQ:FATE)
www.capitalcube.com - September 9 at 4:50 PM
News IconFate Therapeutics, Memorial Sloan Partner on Off-the-Shelf T-Cell Immunotherapies - Drug Discovery & Development (NASDAQ:FATE)
www.dddmag.com - September 9 at 9:47 AM
News IconShares Higher in Today's Session: Fate Therapeutics, Inc. (NASDAQ:FATE) - Post News (NASDAQ:FATE)
www.kentuckypostnews.com - September 8 at 4:53 PM
News IconFate Therapeutics, MSK to Develop Off-the-Shelf T-Cell ... - Genetic Engineering & Biotechnology News (blog) (NASDAQ:FATE)
www.genengnews.com - September 8 at 4:53 PM
biz.yahoo.com logoFATE THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:FATE)
biz.yahoo.com - September 7 at 5:05 PM
News IconFate Therapeutics and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T ... - EconoTimes (NASDAQ:FATE)
www.econotimes.com - September 7 at 8:16 AM
publicnow.com logoFate Therapeutics and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T-Cell Immunotherapies (NASDAQ:FATE)
www.publicnow.com - September 7 at 8:16 AM
kcregister.com logoMorning Buzz: Fate Therapeutics, Inc. (NASDAQ:FATE), Bio-Path Holdings, Inc. (NASDAQ:BPTH), Ford Motor ... - KC Register (NASDAQ:FATE)
www.kcregister.com - September 2 at 9:52 AM
News IconWhat is end result of Analyst Consensus? Fate Therapeutics, Inc. (NASDAQ:FATE) , Pacific DataVision, Inc. (NASDAQ ... - Wall Street Times (press release) (NASDAQ:FATE)
www.wallstreetnews24.com - September 2 at 9:52 AM
finance.yahoo.com logoFate Therapeutics to Present at Upcoming Investor Conferences - Yahoo Finance (NASDAQ:FATE)
finance.yahoo.com - September 1 at 6:26 AM
publicnow.com logoFate Therapeutics to Present at Upcoming Investor Conferences (NASDAQ:FATE)
www.publicnow.com - August 31 at 4:51 PM
capitalcube.com logoETF’s with exposure to Fate Therapeutics, Inc. : August 29, 2016 (NASDAQ:FATE)
www.capitalcube.com - August 29 at 4:53 PM
live-pr.com logoFate Therapeutics, Inc. (FATE) - Financial and Strategic SWOT Analysis Review - New Market Report (NASDAQ:FATE)
www.live-pr.com - August 22 at 9:37 AM
4-traders.com logoFate Therapeutics : Announces $10.3 Million Common Stock Private Placement (NASDAQ:FATE)
www.4-traders.com - August 20 at 9:10 AM
News IconInstitutions Have Decreased Their Ownership of Fate Therapeutics, Inc. (NASDAQ:FATE) - Post News (NASDAQ:FATE)
www.kentuckypostnews.com - August 19 at 6:22 AM
News IconFate Therapeutics, Inc.'s (FATE): Significant Runner - Hot Stocks Point - Hot Stocks Point (NASDAQ:FATE)
www.hotstockspoint.com - August 19 at 6:22 AM
publicnow.com logoFate Therapeutics Announces $10.3 Million Common Stock Private Placement (NASDAQ:FATE)
www.publicnow.com - August 19 at 6:22 AM
finance.yahoo.com logoFATE THERAPEUTICS INC Financials (NASDAQ:FATE)
finance.yahoo.com - August 17 at 5:08 PM
capitalcube.com logoETF’s with exposure to Fate Therapeutics, Inc. : August 12, 2016 (NASDAQ:FATE)
www.capitalcube.com - August 12 at 5:00 PM
capitalcube.com logoFate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:FATE)
www.capitalcube.com - August 11 at 5:06 PM
News IconMix Wondering Stocks- Celldex Therapeutics (NASDAQ:CLDX), Fate Therapeutics (NASDAQ:FATE), Zoetis (NYSE:ZTS) - Seneca Globe (NASDAQ:FATE)
www.senecaglobe.com - August 10 at 5:11 PM

Social

Fate Therapeutics (NASDAQ:FATE) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff